Israeli AI company CytoReason expands contract with US company Pfizer, raises up to approximately 15.4 billion yen
Pfizer extends its faith in CytoReason for AI-driven drug discovery
Pfizer and CytoReason collaborate to bolster AI in drug discovery
Pfizer and CytoReason extend partnership for AI-driven drug discovery
CytoReason, Pfizer ink $110M, 5-year extension of AI-powered drug development deal
Pfizer extends partnership with CytoReason to use AI for drug discovery
AI becomes higher priority for drug discovery with Pfizer, CytoReason deal extension
CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
CytoReason, Pfizer sign $110m extended AI-based drug development deal
CytoReason Expands its 2019 Collaboration with Pfizer for AI Drug Development
